A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

PHASE3CompletedINTERVENTIONAL
Enrollment

793

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
ObesityOverweight
Interventions
DRUG

Naltrexone SR 32 mg/ bupropion SR 360 mg/ day

DRUG

Placebo

BEHAVIORAL

Intensive group lifestyle modification counseling

Trial Locations (9)

10025

New York Obesity Research Center, St. Luke's-Roosevelt Hospital Center, New York

19104

Center for Weight and Eating Disorders, School of Med., University of Penn., Philadelphia

19140

Center for Obesity Research and Education, Temple University, Philadelphia

29425

Medical University of S. Carolina Weight Management Center, Charleston

32611

Univ. of Florida, College of Public Health, and Health Professions, Gainesville

63110

Washington Univ. Center for Human Nutrition, St Louis

77030

Behavioral Medicine Research Center, Houston

80220

Center for Human Nutrition, University of Colorado Health Services Center, Denver

92093

University of California, San Diego: Dept of Family & Preventive Medicine, La Jolla

Sponsors
All Listed Sponsors
lead

Orexigen Therapeutics, Inc

INDUSTRY